-
NMPA Issues the Announcement on Implementing the 2020 Edition of the Pharmacopoeia of the People's Republic of China
2020-07-03
The 2020 Edition of the Pharmacopoeia of the People's Republic of China (hereinafter referred to as 2020 Chinese Pharmacopoeia) has been issued by NMPA and NHC Announcement.
-
Announcement of National Medical Products Administration and National Health Commission on Issuing the 2020 Edition of the Pharmacopoeia of the People's Republic of China
2020-07-02
On July 2, 2020, National Medical Products Administration and National Health Commission issued an announcement on the 2020 Edition of the Pharmacopoeia of the People's Republic of China.
-
NMPA Issues the Revised Draft of the Blood Products Appendix in the Good Manufacturing Practice for Drugs (2010 Revision)
2020-07-02
NMPA has revised the Blood Products Appendix. The Appendix was issued as a supporting document for the Good Manufacturing Practice for Drugs (2010 Revision) on July 2, 2020, and shall come into force as of October 1, 2020.
-
NMPA Issues Announcement on Requirements for the Management of Drug Records and Data (Interim)
2020-07-01
NMPA has organized to formulate the Requirements for the Management of Drug Records and Data (Interim), which has been issued on June 24, 2020 and shall take effect as from December 1, 2020.
-
NMPA Issues the Requirements for Registration Classification and Application Dossiers of Biological Products
2020-06-30
NMPA has organized to formulate the Requirements for Registration Classification and Application Dossiers of Biological Products, which has been issued on June 29, 2020.
-
NMPA Issues Requirements for Registration Classification and Application Dossiers of Chemical Drugs
2020-06-30
NMPA has organized to formulate the Requirements for Registration Classification and Application Dossiers of Chemical Drugs, which has been issued on June 29, 2020.